Cullinan's Velinotamig reduces disease activity in 8 of 9 evaluable patients in early lupus study
CGEM•Cullinan Therapeutics said eight of nine evaluable patients in Genrix Bio’s Phase 1b/2a velinotamig trial for refractory systemic lupus erythematosus showed clinically meaningful improvement. Four patients achieved complete renal responses within 24 weeks.
1. Early trial results
By September 8, 12 patients had received treatment. Five of seven patients with elevated urinary protein showed marked reductions, and four achieved complete renal responses within 24 weeks. No dose-limiting toxicities or severe cytokine release syndrome occurred; two patients had mild or moderate cytokine release syndrome that resolved with treatment. Results are scheduled for presentation at ACR Convergence 2026 on November 8.
